Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-10-21 Regulatory Filings
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycons FYB201/Ranivisio sets innovative standard as Europes First Ranibizumab Biosimilar available in Pre-filled Syringe
Regulatory Filings Classification · 100% confidence The document is a corporate press release announcing the market launch of a new product (FYB201/Ranivisio) by Formycon AG. It details the product's features, the commercial partnership with Teva Pharmaceutical Industries, and the rollout strategy. It does not contain financial statements, audit results, or regulatory filings required by law, but rather serves as a standard corporate news announcement disseminated via the EQS News service. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-10-21 English
Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycons Eylea biosimilar FYB203 (aflibercept) for Australia and Latin America
M&A Activity Classification · 100% confidence The document is a press release issued by Formycon AG announcing new commercialization partnerships for its biosimilar product FYB203 in Australia and Latin America. It details the nature of the agreements, the partners involved, and the strategic impact. As it is a corporate news announcement regarding business operations and partnerships rather than a formal financial report, proxy statement, or regulatory filing, it falls under the category of general corporate news/regulatory announcements.
2025-10-16 English
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Formycon AG stating that they will publish their quarterly/interim financial reports on a future date (November 13, 2025). It provides links to where the reports will be available. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore falls under the Report Publication Announcement (RPA) category.
2025-10-08 English
Hinweis auf Zwischenmitteilung der Geschäftsführung vom 01.07.2025 bis zum 30.09.2025
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 800 characters) that informs stakeholders about the availability of an interim management report for the period 01.07.2025 to 30.09.2025. It provides a link to the company's website where the actual report can be accessed. Following the 'Menu vs Meal' rule, this is an announcement of a report publication rather than the report itself, making it a Report Publication Announcement (RPA).
2025-10-08 German
Hinweis auf Zwischenmitteilung der Geschäftsführung vom 01.07.2025 bis zum 30.09.2025
Report Publication Announcement Classification · 100% confidence The document is a short notification (773 characters) announcing the availability of an interim management report ('Zwischenmitteilung der Geschäftsführung') for the period 01.07.2025 to 30.09.2025. It provides a link to the company's website where the actual report can be found. Per the 'Menu vs Meal' rule, since this is a short announcement regarding the publication of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-10-08 German
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Legal Proceedings Report Classification · 100% confidence The document is a corporate press release announcing a settlement and license agreement between Formycon AG and Regeneron Pharmaceuticals regarding patent litigation for a biosimilar product. While it discusses legal matters, it is a standard corporate news announcement disseminated via a news service (EQS). It does not fit the specific criteria for a legal proceedings report (which typically involves court filings or updates on ongoing litigation status) or other specialized categories. As it is a general corporate announcement, it falls under the Regulatory Filings (RNS) category.
2025-10-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.